Literature DB >> 2201190

Induction of labor with mifepristone (RU 486) in intrauterine fetal death.

D Cabrol1, C Dubois, H Cronje, J M Gonnet, M Guillot, B Maria, J Moodley, J F Oury, J M Thoulon, A Treisser.   

Abstract

In a double-blind controlled multicentric study involving 94 patients with an intrauterine fetal death, we investigated the efficacy and tolerance of mifepristone (RU 486), a steroid compound that antagonizes progesterone action at the receptor level. Success of treatment was defined as the occurrence of fetal expulsion within 72 hours after the first drug intake. Mifepristone treatment (600 mg per day for 2 days) was considered to be effective in 29 of 46 patients (63%). There were only eight successes in 48 patients (17.4%) in the placebo group (p = 0.001, chi 2 test). Tolerance was good in the mifepristone group. In the placebo group, disseminated intravascular coagulation occurred in one woman for whom the investigator waited several weeks for spontaneous expulsion. This large double-blind controlled study provides evidence that mifepristone is of interest in the management of intrauterine fetal death. It could provide a pharmacologic alternative to the use of prostaglandins in this indication.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2201190     DOI: 10.1016/0002-9378(90)91193-g

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  13 in total

Review 1.  Mifepristone. Separating fact from fiction.

Authors:  R C Henshaw; A A Templeton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

Review 2.  Proven and potential clinical applications of mifpristone (RU486).

Authors:  Irving M Spitz
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

3.  Clinical pharmacokinetics of mifepristone.

Authors:  O Heikinheimo
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

4.  Medical abortion.

Authors:  M Heard; J Guillebaud
Journal:  BMJ       Date:  1992-01-25

5.  Route of Delivery in Women With Stillbirth: Results From the Stillbirth Collaborative Research Network.

Authors:  Annelee Boyle; Jessica P Preslar; Carol J R Hogue; Robert M Silver; Uma M Reddy; Robert L Goldenberg; Barbara J Stoll; Michael W Varner; Deborah L Conway; George R Saade; Radek Bukowski; Donald J Dudley
Journal:  Obstet Gynecol       Date:  2017-04       Impact factor: 7.661

6.  Second-Trimester Medical Abortion with Misoprostol Preceded by Two Sequential Doses of Mifepristone: An Observational Study.

Authors:  Usham Shantikumar; Rashmi Bagga; Jasvinder Kalra; Vanita Jain; Vanita Suri; Anju Singh; Neelam Choudhary
Journal:  J Obstet Gynaecol India       Date:  2021-07-13

Review 7.  Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.

Authors:  R N Brogden; K L Goa; D Faulds
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

Review 8.  Medical treatments for incomplete miscarriage (less than 24 weeks).

Authors:  James P Neilson; Gillian Ml Gyte; Martha Hickey; Juan C Vazquez; Lixia Dou
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 9.  Mifepristone for induction of labour.

Authors:  Dharani Hapangama; James P Neilson
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

Review 10.  Medical treatments for incomplete miscarriage.

Authors:  Caron Kim; Sharmani Barnard; James P Neilson; Martha Hickey; Juan C Vazquez; Lixia Dou
Journal:  Cochrane Database Syst Rev       Date:  2017-01-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.